AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02481869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arthrocentesis/Saline
Description: Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
Study NCT04836845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focus extracorporeal shock wave therapy
Description: Focus extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study NCT04836845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: Radial extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study NCT03872973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses.
Study NCT04836845 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham extracorporeal shock wave therapy
Description: Sham extracorporeal shock wave therapy, device: Electronica, Pagani, Italy
Study NCT01818999 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STEREOTACTIC BODY RADIATION THERAPY
Description: SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
Study NCT03792672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine intravenous infusion.
Study NCT02542787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSN16R
Description: Small molecule
Study NCT02542787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dummy tablet
Study NCT03039699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Study NCT03039699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00453999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 200 mg
Description: Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
Study NCT00453999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir 400 mg
Description: Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
Study NCT00453999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
Study NCT03778151 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
Study NCT03778151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
Study NCT00802412 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate
Description: Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
Study NCT00361088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: Phase I and II: 1.3mg/m2 iv days 1,4,8,11
Study NCT00361088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R11577
Description: Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)
Study NCT02911285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1200mg bid (2400mg/day)
Study NCT02911285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills bid
Study NCT02911285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT for AUD/SUD, one hour/once a week
Study NCT02911285 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: CBT for AUD/SUD, one hour/once a week
Study NCT02693405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Executive functions
Description: measures of executive functioning with tasks
Study NCT02619825 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echography
Description: cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
Study NCT01246336 — intervention group
Intervention type: OTHER
Intervention: collection of exhaled breath
Description: no intervention
Study NCT02693405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: social cognition
Description: measures of socio-cognitive functioning with tasks
Study NCT02693405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life
Description: measures of quality of life with questionnaires
Study NCT03939936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psoriatic measurements
Description: Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Study NCT03939936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psoriatic measurements
Description: Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Study NCT03872973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strobe Glasses
Description: Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
Study NCT03939936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Study NCT05153993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascia stretch
Description: Stretch of the fascia plantaris during 3x30, 5x/week, 6 weeks
Study NCT00425321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-445380 100 mg
Description: RWJ-445380 100 mg once daily for up to 12 weeks
Study NCT00425321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-445380 200 mg
Description: RWJ-445380 200 mg once daily for up to 12 weeks
Study NCT03939936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saliva samples
Description: Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Study NCT03939936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saliva samples
Description: Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
Study NCT03193736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINIject implant
Description: MINIject implant is used to reduce intra-ocular pressure (IOP) in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery.
Study NCT00425321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-445380 300 mg
Description: RWJ-445380 300 mg once daily for up to 12 weeks
Study NCT00425321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for up to 12 weeks
Study NCT04156464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
Study NCT04156464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
Study NCT06462755 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study NCT02969421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cough method for placement of tenaculum
Description: The intervention in this arm is the placement of tenaculum via cough method
Study NCT02969421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow Tenaculum Placement of tenaculum
Description: The intervention in this arm is the placement of tenaculum via slow method
Study NCT02340481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride + simethicone chewable tablet
Description: Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
Study NCT00963040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: 4 actuations in each nostril for a total dose of 32 IU
Study NCT00963040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: 4 actuations in each nostril
Study NCT00963040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon
Description: 8 actuations in each nostril for a total dose of 64 IU
Study NCT00963040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: 8 actuations in each nostril
Study NCT02340481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide hydrochloride
Description: Each capsule contains 2 mg of loperamide hydrochloride
Study NCT02340481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide hydrochloride + simethicone chewable placebo tablet
Description: Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
Study NCT02340481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide hydrochloride placebo capsule
Description: Placebo matched to loperamide hydrochloride capsule.
Study NCT01800136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation
Description: Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
Study NCT03815006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free Style Libre 2
Description: FreeStyle Libre 2 (FSL2) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
Study NCT03737305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMJ Condilar Distraction Device
Description: The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
Study NCT03737305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
Study NCT03570658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7049389
Description: RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
Study NCT03570658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally at a dose and frequency matched to RO7049389.
Study NCT02120274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
Study NCT02120274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B 12
Description: Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
Study NCT03418727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: Two products delivered in sequence twice daily.
Study NCT03418727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Mono Therapy
Description: Brimonidine given twice daily along with placebo drops
Study NCT03418727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium carboxymethylcellulose
Description: Placebo given twice daily.
Study NCT03418727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid Eye Drop
Description: Eye drop to be administered after Brimonidine in treatment arm 1
Study NCT01110603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4827
Description: Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
Study NCT01110603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
Study NCT01110603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
Study NCT01110603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
Study NCT01756846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
Study NCT01756846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: use of HEART risk score
Description: During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
Study NCT04839549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: Dextenza 0.4Mg Ophthalmic Insert
Study NCT04839549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoromethalone .01%
Description: Fluoromethalone .01%
Study NCT03725761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
Study NCT00533624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Sodium Delayed Release Tablets
Description: Myfortic® 1,440 mg/day
Study NCT00533624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Cellcept® 2,000 mg/day
Study NCT04223908 — intervention group
Intervention type: OTHER
Intervention: observational : questionnaries for assessment of health burden
Description: The French IN-FOCUS study was designed to capture current and retrospective data in FCS or MCS. Patients were called by the participating centers and were proposed to answer a paper questionnaire or to connect to a web-based questionnaire The questionnaire was divided into sections specifically assessing various domains of their experience: demographic data, signs, symptoms and complications of the disease, healthcare circuit, management, relationship with healthcare providers, and burden of the disease on daily life. (Details are available as supplementary material S1). The questionnaire focused on symptoms because the interest of quality of life assessment tools is debated in rare diseases with episodic manifestations. Indeed, most of these tools refer to a limited recall period.
Study NCT01670435 — intervention group
Intervention type: DRUG
Intervention: Ciprofloxacin (BAYQ3939)
Description: Patient treated with Ciproxan as a first line treatment in daily clinical practice
Study NCT02731443 — intervention group
Intervention type: PROCEDURE
Intervention: Epilepsy surgery
Description: Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
Study NCT02731443 — intervention group
Intervention type: PROCEDURE
Intervention: Depth electrodes insertion
Description: Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
Study NCT02619825 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Elastography
Description: cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
Study NCT00682812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 cervical takings and 2 sampling of blood
Description: * 2 cervical takings~* 2 sampling of blood before and after the total hysterectomy
Study NCT00802412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
Study NCT02236429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaginal flora transplant
Study NCT00682812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 cervical takings and 2 sampling of blood
Description: * cervical taking during the cervical conization~* 2 sampling of blood before and after the intervention
Study NCT04769921 — intervention group
Intervention type: DEVICE
Intervention: dental implants and abutments from Nobel Biocare
Description: The implants will be inserted in an All-on-4 configuration; Abutments will be connected to the implants and serve as support for a full-arch implant-supported restoration.
Study NCT03037827 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Description: Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
Study NCT03037827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
Study NCT00682812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2 cervical takings and 2 sampling of blood
Description: * cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation~* 2 sampling of blood before and after the intervention
Study NCT05349708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE-FACS
Description: Telehealth home-monitoring tablet and blood pressure cuff
Study NCT01883466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography study
Description: Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
Study NCT01555333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: A flexible dose titration will be utilized. Orally disintegrating tablets